Topics:

Genzyme reports new survival data with clofarabine

Genzyme reports new survival data with clofarabine

Genzyme updated information for their CLASSIC II investigational study on Clolar (clofarabine). The estimated median overall survival data was 72 weeks for patients achieving complete remission, the company said. The estimated median survival for acute myeloid leukemia patients achieving overall remission was 59 weeks. The new estimated median duration of remission data and disease-free survival data suggest Clolar produced durable remissions in the patient population, according to the company.

 
Loading comments...
Please Wait 20 seconds or click here to close